Please login to the form below

Not currently logged in
Email:
Password:

chronic spontaneous urticaria

This page shows the latest chronic spontaneous urticaria news and features for those working in and with pharma, biotech and healthcare.

Novartis funds chronic urticaria app and patient community

Novartis funds chronic urticaria app and patient community

Novartis funds chronic urticaria app and patient community. My Hives has been developed, and will be run, by Exco InTouch. ... Novartis is funding a new mobile app and website that aims to create an online support community for patients with chronic

Latest news

  • 90TEN and ICG win market research award at Communiqué 2015 90TEN and ICG win market research award at Communiqué 2015

    Their'Wheals of Despair'campaign, created for Novartis UK, focused on chronic spontaneous urticaria (CSU) - a condition that was until recently a mystery to many doctors and almost completely unknown to

  • NICE set to back Novartis' Xolair for skin condition CSU NICE set to back Novartis' Xolair for skin condition CSU

    NICE set to back Novartis' Xolair for skin condition CSU. Issues final draft guidance on the treatment's use as an add-on for chronic spontaneous urticaria. ... NICE is poised to recommend Novartis' Xolair as an add-on treatment option for severe chronic

  • Novartis' dermatology plans advance with Xolair approval Novartis' dermatology plans advance with Xolair approval

    Novartis' dermatology plans advance with Xolair approval. Green light for use in chronic spontaneous urticaria. ... Novartis' asthma drug Xolair has been approved in Europe for a new indication, the treatment of a severe form of hives known as chronic

  • CHMP backs Xolair for severe hives CHMP backs Xolair for severe hives

    The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Xolair (omalizumab) for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU). ... Chronic urticaria affects around 1 per cent of the

  • Novartis' omalizumab effective in chronic skin disease Novartis' omalizumab effective in chronic skin disease

    The active ingredient in Xolair (omalizumab) has been found to be effective as a treatment for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU) in the ... Novartis filed for approval of omalizumab a few weeks ago as a

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics